A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 7, 2015, Pages 4181-4189

  Via, Laura E ^a   England, Kathleen ^a   Weiner, Danielle M ^a   Schimel, Daniel ^a   Zimmerman, Matthew D ^b   Dayao, Emmanuel ^a   Chen, Ray Y ^a   Dodd, Lori E ^a   Richardson, Mike ^a   Robbins, Katherine K ^a   Cai, Ying ^a   Hammoud, Dima ^c   Herscovitch, Peter ^c   Dartois, Véronique ^b   Flynn, JoAnne L ^d   Barry, Clifton E ^a,e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; DRUG COMBINATION; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; CALLITHRIX; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG MONITORING; LUNG TUBERCULOSIS; LUNG VOLUME; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT RESPONSE; ANIMAL; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG COMBINATION; FEMALE; GRANULOMA; MALE; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT DISEASE; TUBERCULOSIS; X-RAY COMPUTED TOMOGRAPHY;

ANIMALS; ANTITUBERCULAR AGENTS; CALLITHRIX; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; FEMALE; FLUORODEOXYGLUCOSE F18; GRANULOMA; MALE; MYCOBACTERIUM TUBERCULOSIS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RECURRENCE; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS;

EID: 84931287814     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00115-15     Document Type: Article

References (49)

1. th ed. World Health Organization, Geneva, Switzerland.
2. Fox W, Ellard GA, Mitchison DA. 1999. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 3:S231-S279.
3. Azhar GS. 2012. DOTS for TB relapse in India: a systematic review. Lung India 29:147-153. http://dx.doi.org/10.4103/0970-2113.95320.
4. Cox HS, Morrow M, Deutschmann PW. 2008. Long term efficacy of DOTS regimens for tuberculosis: systematic review. BMJ 336:484-487. http://dx.doi.org/10.1136/bmj.39463.640787.BE.
5. Zumla AI, Gillespie SH, Hoelscher M, Philips PP, Cole ST, Abubakar I, McHugh TD, Schito M, Maeurer M, Nunn AJ. 2014. New antituberculosis drugs, regimens, and adjunct therapies: needs, advances, and future prospects. Lancet Infect Dis 14:327-340. http://dx.doi.org/10.1016/S1473-3099(13)70328-1.
6. Owens JP, Fofana MO, Dowdy DW. 2013. Cost-effectiveness of novel first-line treatment regimens for tuberculosis. Int J Tuberc Lung Dis 17:590-596. http://dx.doi.org/10.5588/ijtld.12.0776.
7. Selassie AW, Pozsik C, Wilson D, Ferguson PL. 2005. Why pulmonary tuberculosis recurs: a population-based epidemiological study. Ann Epidemiol 15:519-525. http://dx.doi.org/10.1016/j.annepidem.2005.03.002.
8. Phillips PP, Fielding K, Nunn AJ. 2013. An evaluation of culture results during treatment for tuberculosis as surrogate endpoints for treatment failure and relapse. PLoS One 8:e63840. http://dx.doi.org/10.1371/journal.pone.0063840.
9. Benator D, Bhattacharya M, Bozeman L, Burman W, Cantazaro A, Chaisson R, Gordin F, Horsburgh CR, Horton J, Khan A, Lahart C, Metchock B, Pachucki C, Stanton L, Vernon A, Villarino ME, Wang YC, Weiner M, Weis S, Tuberculosis Trials Consortium. 2002. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet 360:528-534. http://dx.doi.org/10.1016/S0140-6736(02)09742-8.
10. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. 2009. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 180:558-563. http://dx.doi.org/10.1164/rccm.200904-0536OC.
11. Franzblau SG, DeGroote MA, Cho SH, Andries K, Nuermberger E, Orme IM, Mdluli K, Angulo-Barturen I, Dick T, Dartois V, Lenaerts AJ. 2012. Comprehensive analysis of methods used for the evaluation of compounds against Mycobacterium tuberculosis. Tuberculosis (Edinb) 92: 453-488. http://dx.doi.org/10.1016/j.tube.2012.07.003.
12. Nuermberger E, Rosenthal I, Tyagi S, Williams KN, Almeida D, Peloquin CA, Bishai WR, Grosset JH. 2006. Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother 50:2621-2625. http://dx.doi.org/10.1128/AAC.00451-06.
13. Nuermberger EL, Yoshimatsu T, Tyagi S, Williams K, Rosenthal I, O'Brien RJ, Vernon AA, Chaisson RE, Bishai WR, Grosset JH. 2004. Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 170:1131-1134. http://dx.doi.org/10.1164/rccm.200407-885OC.
14. Driver ER, Ryan GJ, Hoff DR, Irwin SM, Basaraba RJ, Kramnik I, Lenaerts AJ. 2012. Evaluation of a mouse model of necrotic granuloma formation using C3HeB/FeJ mice for testing of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 56:3181-3195. http://dx.doi.org/10.1128/AAC.00217-12.
15. Harper J, Skerry C, Davis SL, Tasneen R, Weir M, Kramnik I, Bishai WR, Pomper MG, Nuermberger EL, Jain SK. 2012. Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis 205:595-602. http://dx.doi.org/10.1093/infdis/jir786.
16. Dutta NK, Alsultan A, Gniadek TJ, Belchis DA, Pinn ML, Mdluli KE, Nuermberger EL, Peloquin CA, Karakousis PC. 2013. Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother 57:3910-3916. http://dx.doi.org/10.1128/AAC.00761-13.
17. Ordonez AA, Pokkali S, DeMarco VP, Klunk M, Mease RC, Foss CA, Pomper MG, Jain SK. 2015. Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother 59:642-649. http://dx.doi.org/10.1128/AAC.04180-14.
18. Via LE, Weiner DM, Schimel D, Lin PL, Dayao E, Tankersley SL, Cai Y, Coleman MT, Tomko J, Paripati P, Orandle M, Kastenmayer RJ, Tartakovsky M, Rosenthal A, Portevin D, Eum SY, Lahouar S, Gagneux S, Young DB, Flynn JL, Barry CE, III. 2013. Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect Immun 81:2909-2919. http://dx.doi.org/10.1128/IAI.00632-13.
19. Chen RY, Dodd LE, Lee M, Paripati P, Hammoud DA, Mountz JM, Jeon D, Zia N, Zahiri H, Coleman MT, Carroll MW, Lee JD, Jeong YJ, Herscovitch P, Lahouar S, Tartakovsky M, Rosenthal A, Somaiyya S, Lee S, Goldfeder LC, Cai Y, Via LE, Park SK, Cho SN, Barry CE, III. 2014. PET/CT imaging correlates with treatment outcome in patients with multidrug-resistant tuberculosis. Sci Transl Med 6:265ra166. http://dx.doi.org/10.1126/scitranslmed.3009501.
20. Coleman MT, Chen RY, Lee M, Lin PL, Dodd LE, Maiello P, Via LE, Kim Y, Marriner G, Dartois V, Scanga C, Janssen C, Wang J, Klein E, Cho SN, Barry CE, III, Flynn JL. 2014. PET/CT imaging reveals a therapeutic response to oxazolidinones in macaques and humans with tuberculosis. Sci Transl Med 6:265ra167. http://dx.doi.org/10.1126/scitranslmed.3009500.
21. 18fluorodeoxyglucose positron emission tomography coregistered with computed tomography predict outcome after Mycobacterium tuberculosis infection in cynomolgus macaques. Infect Immun 82:2400-2404. http://dx.doi.org/10.1128/IAI.01599-13.
22. Davis SL, Nuermberger EL, Um PK, Vidal C, Jedynak B, Pomper MG, Bishai WR, Jain SK. 2009. Noninvasive pulmonary [18F]-2-fluorodeoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother 53:4879-4884. http://dx.doi.org/10.1128/AAC.00789-09.
23. 18F]2-fluorodeoxy-D-glucose positron emission tomography and computed tomography. Antimicrob Agents Chemother 56:4391-4402. http://dx.doi.org/10.1128/AAC.00531-12.
24. Anonymous. 1974. Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Third report. East African-British Medical Research Councils. Lancet ii:237-240.
25. th ed. National Academies Press, Washington, DC.
26. Kjellsson MC, Via LE, Goh A, Weiner D, Low KM, Kern S, Pillai G, Barry CE, III, Dartois V. 2012. Pharmacokinetic evaluation of the penetration of antituberculosis agents in rabbit pulmonary lesions. Antimicrob Agents Chemother 56:446-457. http://dx.doi.org/10.1128/AAC.05208-11.
27. Via LE, Lin PL, Ray SM, Carrillo J, Allen SS, Eum SY, Taylor K, Klein E, Manjunatha U, Gonzales J, Lee EG, Park SK, Raleigh JA, Cho SN, McMurray DN, Flynn JL, Barry CE, III. 2008. Tuberculous granulomas are hypoxic in guinea pigs, rabbits, and nonhuman primates. Infect Immun 76:2333-2340. http://dx.doi.org/10.1128/IAI.01515-07.
28. Reed MB, Domenech P, Manca C, Su H, Barczak AK, Kreiswirth BN, Kaplan G, Barry CE, III. 2004. A glycolipid of hypervirulent tuberculosis strains that inhibits the innate immune response. Nature 431:84-87. http://dx.doi.org/10.1038/nature02837.
29. Dartois V, Barry CE. 2010. Clinical pharmacology and lesion penetrating properties of second- and third-line antituberculous agents used in the management of multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis. Curr Clin Pharmacol 5:96-114. http://dx.doi.org/10.2174/157488410791110797.
30. Anonymous. 1986. A controlled clinical trial of 3- and 5-month regimens in the treatment of sputum-positive pulmonary tuberculosis in South India. Tuberculosis Research Centre, Madras, and National Tuberculosis Institute, Bangalore. Am Rev Respir Dis 134:27-33.
31. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, Kim DS, Shim TS. 2014. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med 108:654-659. http://dx.doi.org/10.1016/j.rmed.2014.01.010.
32. Pretet S, Grosset J, Perdrizet S. 1978. Short term chemotherapy of tuberculosis. Evaluation of an 18-week-long treatment including pyrazinamide (preliminary results). Bull Int Union Tuberc 53:260-261. (In French.)
33. Fox W. 1981. Whither short-course chemotherapy? Br J Dis Chest 75: 331-357. http://dx.doi.org/10.1016/0007-0971(81)90022-X.
34. McIlleron H, Wash P, Burger A, Norman J, Folb PI, Smith P. 2006. Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients. Antimicrob Agents Chemother 50:1170-1177. http://dx.doi.org/10.1128/AAC.50.4.1170-1177.2006.
35. Um SW, Lee SW, Kwon SY, Yoon HI, Park KU, Song J, Lee CT, Lee JH. 2007. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels. Int J Tuberc Lung Dis 11:972-978.
36. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2008. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. Antimicrob Agents Chemother 52:2138-2148. http://dx.doi.org/10.1128/AAC.00461-07.
37. Ray J, Gardiner I, Marriott D. 2003. Managing antituberculosis drug therapy by therapeutic drug monitoring of rifampicin and isoniazid. Intern Med J 33:229-234. http://dx.doi.org/10.1046/j.1445-5994.2003.00390.x.
38. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-200262150-00001.
39. Smythe W, Khandelwal A, Merle C, Rustomjee R, Gninafon M, Bocar Lo M, Sow OB, Olliaro PL, Lienhardt C, Horton J, Smith P, McIlleron H, Simonsson USH. 2012. A semimechanistic pharmacokinetic-enzyme turnover model for rifampin autoinduction in adult tuberculosis patients. Antimicrob Agents Chemother 56:2091-2098. http://dx.doi.org/10.1128/AAC.05792-11.
40. Boman G. 1974. Serum concentration and half-life of rifampicin after simultaneous oral administration of aminosalicylic acid or isoniazid. Eur J Clin Pharmacol 7:217-225. http://dx.doi.org/10.1007/BF00560384.
41. McIlleron H, Wash P, Burger A, Folb P, Smith P. 2002. Widespread distribution of a single drug rifampicin formulation of inferior bioavailability in South Africa. Int J Tuberc Lung Dis 6:356-361.
42. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. 2011. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. Br J Clin Pharmacol 72:51-62. http://dx.doi.org/10.1111/j.1365-2125.2011.03940.x.
43. Ruslami R, Nijland HM, Adhiarta IG, Kariadi SH, Alisjahbana B, Aarnoutse RE, van Crevel R. 2010. Pharmacokinetics of antituberculosis drugs in pulmonary tuberculosis patients with type 2 diabetes. Antimicrob Agents Chemother 54:1068-1074. http://dx.doi.org/10.1128/AAC.00447-09.
44. Jonsson S, Davidse A, Wilkins J, Van der Walt JS, Simonsson US, Karlsson MO, Smith P, McIlleron H. 2011. Population pharmacokinetics of ethambutol in South African tuberculosis patients. Antimicrob Agents Chemother 55:4230-4237. http://dx.doi.org/10.1128/AAC.00274-11.
45. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ, Simonsson US. 2006. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. Eur J Clin Pharmacol 62:727-735. http://dx.doi.org/10.1007/s00228-006-0141-z.
46. Zhu M, Burman WJ, Jaresko GS, Berning SE, Jelliffe RW, Peloquin CA. 2001. Population pharmacokinetics of intravenous and intramuscular streptomycin in patients with tuberculosis. Pharmacotherapy 21:1037-1045. http://dx.doi.org/10.1592/phco.21.13.1037.34625.
47. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ, REMoxTB Consortium. 2014. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371:1577-1587. http://dx.doi.org/10.1056/NEJMoa1407426.
48. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, Odhiambo J, Amukoye E, Bah B, Kassa F, N'Diaye A, Rustomjee R, de Jong BC, Horton J, Perronne C, Sismanidis C, Lapujade O, Olliaro PL, Lienhardt C, OFLOTUB/Gatifloxacin for Tuberculosis Project. 2014. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371:1588-1598. http://dx.doi.org/10.1056/NEJMoa1315817.
49. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, Hatherill M, Geldenhuys H, McIlleron HM, Zvada SP, Mungofa S, Shah NA, Zizhou S, Magweta L, Shepherd J, Nyirenda S, van Dijk JH, Clouting HE, Coleman D, Bateson AL, McHugh TD, Butcher PD, Mitchison DA, Rifaquin Trial Team. 2014. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371:1599-1608. http://dx.doi.org/10.1056/NEJMoa1314210.